Thursday, April 09, 2020 12:47:13 PM
1. Pre-clinical research: check out your BioPub interviews. These are quick and explain Algernon's plan of action in a concise and clear way. They make the science easy to understand. They discuss the positive data from animal studies that shows our drugs generated positive signal and treated the disease of interest. One aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough. Our lead outperforms the best drug big pharma has to offer.
Ifenprodil works for severe acute lung injury and acute respiratory distress syndrome (ARDS) which is what is killing people who get COVID-19, novel coronavirus.
We are skipping preclinical testing because previous studies have shown are drug is safe. In animal models it greatly reduced mortality from severe viral respiratory disease... just like what we are expecting with COVID. Now we have plans for studying in South Korea, Autralia, and Canada. All in humans via Phase 2 trials.
2. Safety testing usually cost hundreds of millions. We are using repurposed drugs. We have patents protecting Ifenprodil for respiratory diseases - and it's sister drug. We are saving the hundreds of millions by using the safe drugs. We are doing some FDA-registered clinical trial testing in the USA. We will show it's safe for injection by IV, as well as oral long acting.
3. Clinical trials: We have NOVOTECH which is a certified CRO which is going to be running our trials. We have funding. We have drug ready to go. We are also producing more drug using a certified American chemistry company. We have NOVOTECH investing there own money in Algernon. FDA and medical regulatory authorities in Australia and South Korea and Canada will fast track ifenprofil for COVID-19 related use. Ethics can get approved in days to weeks. Maybe by next week for the South Korea study.
4. Why it works:
Coronaviruses may invade the nervous system and we have a drug that protects the neurons. COVID-19 may invade neurons causing respiratory failure. Coronaviruses invade the nervous system.
Here is proof:
PROOF Coronaviruses infect neurons
Our drug protects them by working on the NMDA receptor.
NMDA receptor
The nervous system invasion by the virus can cause a lot of inflammatory mediators (aka inflammation) to be release and that causes the NMDA receptor to cause neuron injury. This is important because our drug blocks that. Already doctors are publishing work showing covid-19 hurts the nervous system.
And like I said before, here's how our drug works:
This is why NMDA ANTAGONIST IFENPRODIL is going to be helpful for saving neurons! Ifenprodil works on the NMDA receptor on neurons.
And SARS-COV-2 aka COVID-19 hurts the neurons.
This study shows NMDA receptor plays a role in neuronal cell death.
So Ifenprodil may actually help keep the neurons alive. It might help people from failing to breath.
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM